Trending NewsTrending NewsMost-Upgraded StocksMost-UpgradedNASDAQ:AMGN Amgen (AMGN) Stock Price, News & Analysis $459.21 +7.38 (+1.63%) As of 02:35 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Amgen Stock (NASDAQ:AMGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Amgen alerts:Sign Up Key Stats Today's Range$457.36▼$468.2750-Day Range$375.65▼$451.8352-Week Range$288.00▼$468.27Volume1.24 million shsAverage Volume2.74 million shsMarket Capitalization$248.26 billionP/E Ratio28.50Dividend Yield2.20%Price Target$389.71Consensus RatingHold Company Overview Amgen Inc. is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers. Founded in 1980, Amgen is headquartered in Thousand Oaks, California. The company serves patients and healthcare providers in the United States and international markets through its research, manufacturing and commercial operations. Amgen is led by Chairman and Chief Executive Officer Robert A. Bradway.AI Generated. May Contain Errors. Read More Amgen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreAMGN MarketRank™: 3.71599845301 of 5 starsAmgen scored higher than 74% of companies evaluated by MarketBeat, and ranked 160th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingAmgen has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 1 strong buy rating, 10 buy ratings, 16 hold ratings, and 3 sell ratings.Downside RiskAmgen has a consensus price target of $389.71, representing about 14.9% downside from its current price of $458.13.Amount of Analyst CoverageAmgen has been the subject of 23 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amgen's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth7.19% Earnings GrowthEarnings for Amgen are expected to grow by 7.19% in the coming year, from $22.96 to $24.61 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amgen is 28.46, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.08.Price to Earnings Ratio vs. SectorThe P/E ratio of Amgen is 28.46, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 37.09.Price to Earnings Growth RatioAmgen has a PEG Ratio of 3.21. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmgen has a P/B Ratio of 28.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amgen's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.50% of the float of Amgen has been sold short.Short Interest Ratio / Days to CoverAmgen has a short interest ratio ("days to cover") of 4.97.Change versus previous monthShort interest in Amgen has recently decreased by 4.63%, indicating that investor sentiment is improving. Dividend4.2 / 5Dividend StrengthStrong Dividend YieldAmgen pays a meaningful dividend of 2.29%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAmgen has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of Amgen is 62.65%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Amgen will have a dividend payout ratio of 40.96% next year. This indicates that Amgen will be able to sustain or increase its dividend.Read more about Amgen's dividend. News and Social Media2.8 / 5News Sentiment0.44 News SentimentAmgen has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 56 news articles for Amgen this week, compared to 9 articles on an average week.Search InterestOnly 34 people have searched for AMGN on MarketBeat in the last 30 days. This is a decrease of -3% compared to the previous 30 days.MarketBeat Follows27 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Amgen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,540,926.00 in company stock.Percentage Held by Insiders0.85% of the stock of Amgen is held by insiders.Percentage Held by Institutions76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amgen's insider trading history. Receive AMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMGN Stock News HeadlinesRBC Capital Reaffirms Their Buy Rating on Amgen (AMGN)October 29 at 8:19 AM | theglobeandmail.comAmgen Braces for Rising Expenses Ahead of Q3 Results—Is a Profit Squeeze Looming?October 29 at 5:51 AM | 247wallst.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 29 at 1:00 AM | Weiss Ratings (Ad)Amgen Braces for Rising Expenses Ahead of Q3 Results—Is a Profit Squeeze Looming?October 29 at 5:32 AM | 247wallst.comWhat Could Amgen (AMGN) Rare Disease Updates Mean For Its Growth Story?October 28 at 8:00 PM | finance.yahoo.comAMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTSOctober 28 at 8:00 PM | finance.yahoo.comAMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTSOctober 28 at 4:30 PM | prnewswire.comGoldman Sachs Remains a Buy on Amgen (AMGN)October 27 at 11:15 PM | theglobeandmail.comSee More Headlines AMGN Stock Analysis - Frequently Asked Questions How have AMGN shares performed this year? Amgen's stock was trading at $327.31 at the beginning of the year. Since then, AMGN stock has increased by 40.0% and is now trading at $458.1250. How were Amgen's earnings last quarter? Amgen Inc. (NASDAQ:AMGN) released its quarterly earnings results on Tuesday, August, 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. The firm's revenue for the quarter was up 9.5% compared to the same quarter last year. Read the conference call transcript. Does Amgen have any subsidiaries? Amgen subsidiaries include TeneoBio, Five Prime Therapeutics, Rodeo Therapeutics, Otezla, Nuevolution, Catherex, Catherex, and more. Who are Amgen's major shareholders? Amgen's top institutional shareholders include Assenagon Asset Management S.A. (0.28%), Sumitomo Mitsui Trust Group Inc. (0.27%), Mirae Asset Global Investments Co. Ltd. (0.15%) and ProShare Advisors LLC (0.13%). Insiders that own company stock include Murdo Gordon, David M Reese, Jonathan P Graham, Nancy A Grygiel, Nancy A Grygiel and Rachna Khosla. View institutional ownership trends. How do I buy shares of Amgen? Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amgen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amgen investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), AbbVie (ABBV), Pfizer (PFE), Bristol Myers Squibb (BMY), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Last Earnings8/04/2026Record date for 9/11 Dividend8/21/2026Ex-Dividend for 9/11 Dividend8/21/2026Dividend Payable9/11/2026Today10/29/2026Next Earnings (Estimated)11/03/2026Record date for 12/11 Dividend11/20/2026Ex-Dividend for 12/11 Dividend11/20/2026Dividend Payable12/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 AMGN's financial health is in the Green zone, according to TradeSmith. AMGN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AMGN CIK318154 Webwww.amgen.com Phone(805) 447-1000Fax805-447-1010Employees31,500Year Founded1980Price Target and Rating Average Price Target for Amgen$389.71 High Price Target$500.00 Low Price Target$200.00 Potential Upside/Downside-15.1%Consensus RatingHold Rating Score (0-4)2.30 Research Coverage30 Analysts Profitability EPS (Trailing Twelve Months)$16.09 Trailing P/E Ratio28.51 Forward P/E Ratio19.99 P/E Growth3.21Net Income$7.71 billion Net Margins22.95% Pretax Margin27.00% Return on Equity124.14% Return on Assets13.18% Debt Debt-to-Equity Ratio4.44 Current Ratio1.37 Quick Ratio1.13 Sales & Book Value Annual Sales$38.10 billion Price / Sales6.51 Cash Flow$35.33 per share Price / Cash Flow12.99 Book Value$16.08 per share Price / Book28.54Miscellaneous Outstanding Shares540,632,000Free Float536,037,000Market Cap$248.15 billion OptionableOptionable Beta0.41 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:AMGN) was last updated on 10/29/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe chip inside every TeslaEvery Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | Sponsored$29.97 or $0 todayThe 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightfo...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amgen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amgen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
